Drug interaction study for RSS0343 tablet in healthy adults
Part of Ear, nose & throat, Lungs & breathing clinical trials.
This trial checks how other drugs affect RSS0343, a tablet being studied. You may qualify if you are a healthy adult who can avoid certain foods and medications during the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- Your body mass index (BMI) is between 19 and 28.
- You are a non-smoker or smoke fewer than 5 cigarettes a day.
- You have not used any prescription or over-the-counter drugs (except occasional acetaminophen or ibuprofen) in the last month.
- You can avoid caffeine, grapefruit, and alcohol during the study period.
- You are willing to use birth control if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine for people with non-cystic fibrosis bronchiectasis. It aims to see if the drug can help reduce symptoms and improve quality of life.
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This study tests whether an investigational tablet called XH-S004 can reduce flare-ups and improve symptoms in people with bronchiectasis (widened airways that trap mucus). It is for adults who produce phlegm daily and have had at least two worsening episodes in the last year.
This trial studies how a new drug (HRS-9813) interacts with two existing lung fibrosis drugs (pirfenidone and nintedanib) in healthy adults. The results will help doctors understand how to combine these medicines safely.
Hear when a new Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.